$45M additional funding bolsters development of canine longevity drugMarch 25, 2024The latest financing round brings the total funds raised for the first FDA-approved dog lifespan extension drug to $125M
SPONSORED CONTENTCurrent users report reduced stress for parvovirus care1Research shows that our Canine Parvovirus Monoclonal Antibody can help veterinary care teams work with less stress.1 Learn what CPMA can do for your parvo protocol. + Read More
Canine longevity drug starts clinical trialFebruary 1, 2024A whippet named Boo is the first dog dosed in the study to demonstrate healthy lifespan extension in dogs treated with LOY-002
